Parcours des patients

Registre international de leucémie myéloïde chronique (LMC) de l’enfant

Pr Xavier Leleu

2020

Barbarin, Alice, Myriam Abdallah, Lucie Lefèvre, Nathalie Piccirilli, Emilie Cayssials, Lydia Roy, Jean-Marc Gombert, et André Herbelin. « Innate T-Αβ Lymphocytes as New Immunological Components of Anti-Tumoral “off-Target” Effects of the Tyrosine Kinase Inhibitor Dasatinib ». Scientific Reports 10, n^o 1 (24 février 2020): 3245. https://doi.org/10.1038/s41598-020-60195-z.

Bender, Sébastien, Vincent Javaugue, Alexis Saintamand, Maria Victoria Ayala, Mehdi Alizadeh, Matthieu Filloux, Virginie Pascal, et al. « Immunoglobulin Variable Domain High-Throughput Sequencing Reveals Specific Novel Mutational Patterns in POEMS Syndrome ». Blood 135, n^o 20 (14 mai 2020): 1750‑58. https://doi.org/10.1182/blood.2019004197.

Hähnel, Tom, Christoph Baldow, Joëlle Guilhot, François Guilhot, Susanne Saussele, Satu Mustjoki, Stefanie Jilg, et al. « Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML ». Cancer Research 80, n^o 11 (1 juin 2020): 2394‑2406. https://doi.org/10.1158/0008-5472.CAN-19-2175.

Hochhaus, A., M. Baccarani, R. T. Silver, C. Schiffer, J. F. Apperley, F. Cervantes, R. E. Clark, et al. « European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia ». Leukemia 34, n^o 4 (avril 2020): 966‑84. https://doi.org/10.1038/s41375-020-0776-2.

Narquin, S., P. Ingrand, I. Azais, V. Delwail, R. Vialle, S. Boucebci, et J.-P. Tasu. « Erratum to “Comparison of Whole-Body Diffusion MRI Andconventional Radiological Assessment in the Staging of Myeloma” [Diagn. Interv. Imaging. 94 (2013), 629-636] ». Diagnostic and Interventional Imaging 101, n^o 5 (2020): 331. https://doi.org/10.1016/j.diii.2019.12.012.

Pladys, Adélaïde, Gautier Defossez, Pierre Lemordant, Mathilde Lassalle, Pierre Ingrand, Christian Jacquelinet, Christine Riou, et al. « Cancer Risk in Dialyzed Patients with and without Diabetes ». Cancer Epidemiology 65 (avril 2020): 101689. https://doi.org/10.1016/j.canep.2020.101689.

Roussel, Murielle, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Anne-Marie Stoppa, Margaret Macro, et al. « Health-Related Quality of Life Results from the IFM 2009 Trial: Treatment with Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma ». Leukemia & Lymphoma 61, n^o 6 (juin 2020): 1323‑33. https://doi.org/10.1080/10428194.2020.1719091.

Roussel, Murielle, Giampaolo Merlini, Sylvie Chevret, Bertrand Arnulf, Anne Marie Stoppa, Aurore Perrot, Giovanni Palladini, et al. « A Prospective Phase 2 Trial of Daratumumab in Patients with Previously Treated Systemic Light-Chain Amyloidosis ». Blood 135, n^o 18 (30 avril 2020): 1531‑40. https://doi.org/10.1182/blood.2019004369.

Söderlund, Stina, Inger Persson, Mette Ilander, Joëlle Guilhot, Henrik Hjorth-Hansen, Perttu Koskenvesa, Johan Richter, Susanne Saussele, Satu Mustjoki, et Ulla Olsson-Strömberg. « Plasma Proteomics of Biomarkers for Inflammation or Cancer Cannot Predict Relapse in Chronic Myeloid Leukaemia Patients Stopping Tyrosine Kinase Inhibitor Therapy ». Leukemia Research 90 (mars 2020): 106310. https://doi.org/10.1016/j.leukres.2020.106310.

 

 

2019

Attal, Michel, Paul G. Richardson, S. Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, et al. « Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study ». Lancet (London, England) 394, n^o 10214 (07 2019): 2096‑2107. https://doi.org/10.1016/S0140-6736(19)32556-5.

Berger, Marc G., Bruno Pereira, Philippe Rousselot, Pascale Cony-Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre-Barbe, et al. « Longer Treatment Duration and History of Osteoarticular Symptoms Predispose to Tyrosine Kinase Inhibitor Withdrawal Syndrome ». British Journal of Haematology 187, n^o 3 (2019): 337‑46. https://doi.org/10.1111/bjh.16083.

Boyle, Eileen M., Xavier Leleu, Marie-Odile Petillon, Lionel Karlin, Chantal Doyen, Hélène Demarquette, Bruno Royer, et al. « Daratumumab and Dexamethasone Is Safe and Effective for Triple Refractory Myeloma Patients: Final Results of the IFM 2014-04 (Etoile Du Nord) Trial ». British Journal of Haematology 187, n^o 3 (2019): 319‑27. https://doi.org/10.1111/bjh.16059.

Bruijn, Clara M. A. de, Frédéric Millot, Meinolf Suttorp, Marina Borisevich, Paul Brons, Birgitte Lausen, et Eveline S. J. M. de Bont. « Discontinuation of Imatinib in Children with Chronic Myeloid Leukaemia in Sustained Deep Molecular Remission: Results of the STOP IMAPED Study ». British Journal of Haematology 185, n^o 4 (2019): 718‑24. https://doi.org/10.1111/bjh.15826.

Camuset, Margaux, Audrey Grain, Fleur Lorton, Odile Minckes, Anne Jourdain, Frédéric Millot, Isabelle Pellier, Virginie Gandemer, et Fanny Rialland Battisti. « [Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion: A chance for all] ». Bulletin Du Cancer 106, n^o 3 (mars 2019): 206‑15. https://doi.org/10.1016/j.bulcan.2018.11.012.

Chaoui, Driss, Maya Hacini, Olivier Fitoussi, Lionel Karlin, Yazid Arkam, Eric Jourdan, Hubert Orfeuvre, et al. « Relapsed or Refractory Chronic Lymphocytic Leukemia Retreated with Rituximab in Daily Practice: Final Results of the PERLE Study ». Leukemia & Lymphoma 60, n^o 6 (2019): 1563‑67. https://doi.org/10.1080/10428194.2018.1533130.

Chiche, Johanna, Julie Reverso-Meinietti, Annabelle Mouchotte, Camila Rubio-Patiño, Rana Mhaidly, Elodie Villa, Jozef P. Bossowski, et al. « GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors ». Cell Metabolism 29, n^o 6 (04 2019): 1243-1257.e10. https://doi.org/10.1016/j.cmet.2019.02.002.

Coignard-Biehler, Hélène, Nizar Mahlaoui, Benoit Pilmis, Vincent Barlogis, Pauline Brosselin, Nathalie De Vergnes, Marianne Debré, et al. « A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency ». Journal of Clinical Immunology 39, n^o 7 (2019): 702‑12. https://doi.org/10.1007/s10875-019-00658-9.

Costello, Caitlin, Faith E. Davies, Gordon Cook, Jorge Vela-Ojeda, Jim Omel, Robert M. Rifkin, Jesus Berdeja, et al. « INSIGHT MM: A Large, Global, Prospective, Non-Interventional, Real-World Study of Patients with Multiple Myeloma ». Future Oncology (London, England) 15, n^o 13 (mai 2019): 1411‑28. https://doi.org/10.2217/fon-2019-0013.

Facon, Thierry, Meletios A. Dimopoulos, Nathalie Meuleman, Andrew Belch, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, et al. « A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM-020) Trial ». Leukemia 34, n^o 1 (2020): 224‑33. https://doi.org/10.1038/s41375-019-0539-0.

Facon, Thierry, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, et al. « Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma ». The New England Journal of Medicine 380, n^o 22 (30 2019): 2104‑15. https://doi.org/10.1056/NEJMoa1817249.

Gallego Hernanz, Maria Pilar, José Miguel Torregrosa Diaz, Nathalie Sorel, Arthur Bobin, Elodie Dindinaud, Sabrina Bouyer, Deborah Desmier, et al. « Long-Term Molecular Remission in a Patient with Acute Myeloid Leukemia Harboring a New NUP98-LEDGF Rearrangement ». Cancer Medicine 8, n^o 4 (2019): 1765‑70. https://doi.org/10.1002/cam4.2051.

Guidez, Stephanie, Laurence Lacotte-Thierry, Cecile Tomowiak, Isabelle Princet, Brigitte Dreyfus, Gaelle Olivier, Emmanuel Fleck, et al. « Oral CHOP-like Chemotherapy in 60-80 Years-Old Patients with Diffuse Large B-Cell Lymphoma ». British Journal of Haematology 186, n^o 6 (2019): e175‑78. https://doi.org/10.1111/bjh.16056.

Guilhot, François. « Ponatinib and Platelets a Conflict in CML ». Blood 133, n^o 14 (04 2019): 1520‑21. https://doi.org/10.1182/blood-2019-02-900472.

Hadjadj, Jérôme, Nathalie Aladjidi, Helder Fernandes, Guy Leverger, Aude Magérus-Chatinet, Fabienne Mazerolles, Marie-Claude Stolzenberg, et al. « Pediatric Evans Syndrome Is Associated with a High Frequency of Potentially Damaging Variants in Immune Genes ». Blood 134, n^o 1 (04 2019): 9‑21. https://doi.org/10.1182/blood-2018-11-887141.

Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, et al. « Phase 2 Study of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia ». Blood 134, n^o 23 (05 2019): 2036‑45. https://doi.org/10.1182/blood.2019000069.

Hofmans, Mattias, Stefan Suciu, Alina Ferster, Pieter Van Vlierberghe, Françoise Mazingue, Nicolas Sirvent, Vitor Costa, et al. « Results of Successive EORTC-CLG 58 881 and 58 951 Trials in Paediatric T-Cell Acute Lymphoblastic Leukaemia (ALL) ». British Journal of Haematology 186, n^o 5 (2019): 741‑53. https://doi.org/10.1111/bjh.15983.

Horwitz, Steven, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, et al. « Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial ». Lancet (London, England) 393, n^o 10168 (19 2019): 229‑40. https://doi.org/10.1016/S0140-6736(18)32984-2.

Houillier, Caroline, Luc Taillandier, Sylvain Dureau, Thierry Lamy, Mouna Laadhari, Olivier Chinot, Cecile Moluçon-Chabrot, et al. « Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study ». Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37, n^o 10 (01 2019): 823‑33. https://doi.org/10.1200/JCO.18.00306.

Ingrand, Isabelle, Ludovic Gaussot, Elisabeth Richard, Griselda Drouet, Fabienne Moreau, et Pierre Ingrand. « [Family risk information for colorectal cancer. Perspectives on the effectiveness of a tailored intervention] ». Sante Publique (Vandoeuvre-Les-Nancy, France) S2, n^o HS2 (2019): 79‑89. https://doi.org/10.3917/spub.197.0079.

Lacourt, Aude, Brice Amadéo, Céline Gramond, Emilie Marrer, Sandrine Plouvier, Isabelle Baldi, Jean-Yves Blay, et al. « ETIOSARC Study : Environmental Aetiology of Sarcomas from a French Prospective Multicentric Population-Based Case-Control Study-Study Protocol ». BMJ Open 9, n^o 6 (18 2019): e030013. https://doi.org/10.1136/bmjopen-2019-030013.

Lauseker, Michael, Katharina Bachl, Anna Turkina, Edgar Faber, Witold Prejzner, Ulla Olsson-Strömberg, Michele Baccarani, et al. « Prognosis of Patients with Chronic Myeloid Leukemia Presenting in Advanced Phase Is Defined Mainly by Blast Count, but Also by Age, Chromosomal Aberrations and Hemoglobin ». American Journal of Hematology 94, n^o 11 (2019): 1236‑43. https://doi.org/10.1002/ajh.25628.

Leleu, Xavier, Guillemette Fouquet, Valentine Richez, Stéphanie Guidez, Alain Duhamel, François Machuron, Lionel Karlin, et al. « Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial ». Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25, n^o 14 (15 2019): 4224‑30. https://doi.org/10.1158/1078-0432.CCR-18-3642.

Mahamdallie, Shazia, Shawn Yost, Emma Poyastro-Pearson, Esty Holt, Anna Zachariou, Sheila Seal, Anna Elliott, et al. « Identification of New Wilms Tumour Predisposition Genes: An Exome Sequencing Study ». The Lancet. Child & Adolescent Health 3, n^o 5 (2019): 322‑31. https://doi.org/10.1016/S2352-4642(19)30018-5.

Millot, Frédéric, Natacha Maledon, Joelle Guilhot, Adalet Meral Güneş, Krzysztof Kalwak, et Meinolf Suttorp. « Favourable Outcome of de Novo Advanced Phases of Childhood Chronic Myeloid Leukaemia ». European Journal of Cancer (Oxford, England: 1990) 115 (2019): 17‑23. https://doi.org/10.1016/j.ejca.2019.03.020.

Pegourie, Brigitte, Lionel Karlin, Lotfi Benboubker, Frédérique Orsini-Piocelle, Mourad Tiab, Sophie Auger-Quittet, Philippe Rodon, et al. « Apixaban for the Prevention of Thromboembolism in Immunomodulatory-Treated Myeloma Patients: Myelaxat, a Phase 2 Pilot Study ». American Journal of Hematology 94, n^o 6 (2019): 635‑40. https://doi.org/10.1002/ajh.25459.

Pertesi, Maroulio, Maxime Vallée, Xiaomu Wei, Maria V. Revuelta, Perrine Galia, Delphine Demangel, Javier Oliver, et al. « Exome Sequencing Identifies Germline Variants in DIS3 in Familial Multiple Myeloma ». Leukemia 33, n^o 9 (2019): 2324‑30. https://doi.org/10.1038/s41375-019-0452-6.

Pincez, Thomas, Bénédicte Neven, Hubert Ducou Le Pointe, Pascale Varlet, Helder Fernandes, Albane Gareton, Guy Leverger, et al. « Neurological Involvement in Childhood Evans Syndrome ». Journal of Clinical Immunology 39, n^o 2 (2019): 171‑81. https://doi.org/10.1007/s10875-019-0594-3.

Richardson, Paul G., Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, et al. « Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial ». The Lancet. Oncology 20, n^o 6 (2019): 781‑94. https://doi.org/10.1016/S1470-2045(19)30152-4.

 

2018

Cabannes-Hamy, Aurélie, Frederic Peyrade, Fabrice Jardin, Jean-François Emile, Vincent Delwail, Nicolas Mounier, Corinne Haioun, et al. « Central Nervous System Relapse in Patients over 80 Years with Diffuse Large B-Cell Lymphoma: An Analysis of Two LYSA Studies ». Cancer Medicine 7, n^o 3 (2018): 539‑48. https://doi.org/10.1002/cam4.1139.

Cayssials, Emilie, Florence Tartarin, Joëlle Guilhot, Nathalie Sorel, Jean Claude Chomel, Xavier Leleu, et François Guilhot. « Sustained Molecular Response in Chronic Myeloid Leukemia Deep Responders Treated with Low Dose Tyrosine Kinase Inhibitors ». Leukemia & Lymphoma 59, n^o 3 (2018): 766‑69. https://doi.org/10.1080/10428194.2017.1357178.

Chantepie, Sylvain P., Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie-Virginie Larcher, Momar Diouf, Luc-Mathieu Fornecker, et al. « Bendamustine-Based Conditioning Prior to Autologous Stem Cell Transplantation (ASCT): Results of a French Multicenter Study of 474 Patients from LYmphoma Study Association (LYSA) Centers ». American Journal of Hematology 93, n^o 6 (juin 2018): 729‑35. https://doi.org/10.1002/ajh.25077.

Desandes, Emmanuel, Laurence Brugières, Florence Molinié, Gautier Defossez, Patricia Delafosse, Karine Jehannin-Ligier, Michel Velten, et al. « Adolescent and Young Adult Oncology Patients in France: Heterogeneity in Pathways of Care ». Pediatric Blood & Cancer 65, n^o 9 (2018): e27235. https://doi.org/10.1002/pbc.27235.

Dimopoulos, Meletios, Katja Weisel, Niels W. C. J. van de Donk, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, et al. « Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial ». Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36, n^o 20 (10 2018): 2035‑43. https://doi.org/10.1200/JCO.2017.76.1742.

Facon, Thierry, Meletios A. Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew Belch, Michele Cavo, Antonello Pinto, et al. « Final Analysis of Survival Outcomes in the Phase 3 FIRST Trial of Up-Front Treatment for Multiple Myeloma ». Blood 131, n^o 3 (18 2018): 301‑10. https://doi.org/10.1182/blood-2017-07-795047.

Fouquet, Guillemette, Kym Ie Snell, Stéphanie Guidez, Susanna Schraen, Eileen Boyle, Loïc Renaud, Déborah Desmier, et al. « Heavy + Light Chain Analysis to Assign Myeloma Response Is Analogous to the IMWG Response Criteria ». Leukemia & Lymphoma 59, n^o 3 (2018): 583‑89. https://doi.org/10.1080/10428194.2017.1339876.

Garderet, Laurent, Simona Iacobelli, Linda Koster, Hartmut Goldschmidt, Jan-Erik Johansson, Jean Henri Bourhis, Marta Krejci, et al. « Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma ». Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 24, n^o 7 (2018): 1372‑78. https://doi.org/10.1016/j.bbmt.2018.01.035.

Jurczyszyn, Artur, Jakub Radocha, Julio Davila, Mark A. Fiala, Alessandro Gozzetti, Norbert Grząśko, Paweł Robak, et al. « Prognostic Indicators in Primary Plasma Cell Leukaemia: A Multicentre Retrospective Study of 117 Patients ». British Journal of Haematology 180, n^o 6 (2018): 831‑39. https://doi.org/10.1111/bjh.15092.

Lamy, Thierry, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, Krimo Bouabdallah, Rémy Gressin, et al. « R-CHOP 14 with or without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma ». Blood 131, n^o 2 (11 2018): 174‑81. https://doi.org/10.1182/blood-2017-07-793984.

Ludwig, Heinz, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay, Philippe Moreau, Hervé Avet-Loiseau, et al. « Prevention and Management of Adverse Events of Novel Agents in Multiple Myeloma: A Consensus of the European Myeloma Network ». Leukemia 32, n^o 7 (2018): 1542‑60. https://doi.org/10.1038/s41375-018-0040-1.

Saussele, Susanne, Johan Richter, Joelle Guilhot, Franz X. Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J. W. M. Janssen, et al. « Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO-SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non-Randomised, Trial ». The Lancet. Oncology 19, n^o 6 (2018): 747‑57. https://doi.org/10.1016/S1470-2045(18)30192-X.

 

 

2017

Aggoune, Djamel, Nathalie Sorel, Marie-Laure Bonnet, Jean-Michel Goujon, Karin Tarte, Olivier Hérault, Jorge Domenech, et al. « Bone Marrow Mesenchymal Stromal Cell (MSC) Gene Profiling in Chronic Myeloid Leukemia (CML) Patients at Diagnosis and in Deep Molecular Response Induced by Tyrosine Kinase Inhibitors (TKIs) ». Leukemia Research 60 (2017): 94‑102. https://doi.org/10.1016/j.leukres.2017.07.007.

Attal, Michel, Valerie Lauwers-Cances, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, et al. « Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma ». The New England Journal of Medicine 376, n^o 14 (06 2017): 1311‑20. https://doi.org/10.1056/NEJMoa1611750.

Barbarin, Alice, Emilie Cayssials, Florence Jacomet, Nicolas Gonzalo Nunez, Sara Basbous, Lucie Lefèvre, Myriam Abdallah, et al. « Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases ». Frontiers in Immunology 8 (2017): 316. https://doi.org/10.3389/fimmu.2017.00316.

Breccia, Massimo, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, et Fabio Efficace. « Physicians’ Attitude towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients ». Health and Quality of Life Outcomes 15, n^o 1 (18 octobre 2017): 204. https://doi.org/10.1186/s12955-017-0788-4.

Chaoui, Driss, Sylvain Choquet, Laurence Sanhes, Béatrice Mahé, Maya Hacini, Olivier Fitoussi, Yazid Arkam, et al. « Relapsed Chronic Lymphocytic Leukemia Retreated with Rituximab: Interim Results of the PERLE Study ». Leukemia & Lymphoma 58, n^o 6 (2017): 1366‑75. https://doi.org/10.1080/10428194.2016.1243673.

Chauvet, Sophie, Véronique Frémeaux-Bacchi, Florent Petitprez, Alexandre Karras, Laurent Daniel, Stéphane Burtey, Gabriel Choukroun, et al. « Treatment of B-Cell Disorder Improves Renal Outcome of Patients with Monoclonal Gammopathy-Associated C3 Glomerulopathy ». Blood 129, n^o 11 (16 2017): 1437‑47. https://doi.org/10.1182/blood-2016-08-737163.

Etienne, Gabriel, Joëlle Guilhot, Delphine Rea, Françoise Rigal-Huguet, Franck Nicolini, Aude Charbonnier, Agnès Guerci-Bresler, et al. « Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia ». Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35, n^o 3 (20 janvier 2017): 298‑305. https://doi.org/10.1200/JCO.2016.68.2914.

Favreau, M., E. Menu, D. Gaublomme, K. Vanderkerken, S. Faict, K. Maes, E. De Bruyne, et al. « Leptin Receptor Antagonism of INKT Cell Function: A Novel Strategy to Combat Multiple Myeloma ». Leukemia 31, n^o 12 (2017): 2678‑85. https://doi.org/10.1038/leu.2017.146.

Garnier, Cyrille, Fatma Briki, Brigitte Nedelec, Patrick Le Pogamp, Ahmet Dogan, Nathalie Rioux-Leclercq, Renan Goude, et al. « VLITL Is a Major Cross-β-Sheet Signal for Fibrinogen Aα-Chain Frameshift Variants ». Blood 130, n^o 25 (21 2017): 2799‑2807. https://doi.org/10.1182/blood-2017-07-796185.

Hájek, R., T. Masszi, M. T. Petrucci, A. Palumbo, L. Rosiñol, A. Nagler, K. L. Yong, et al. « A Randomized Phase III Study of Carfilzomib vs Low-Dose Corticosteroids with Optional Cyclophosphamide in Relapsed and Refractory Multiple Myeloma (FOCUS) ». Leukemia 31, n^o 1 (2017): 107‑14. https://doi.org/10.1038/leu.2016.176.

Hochhaus, Andreas, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, et al. « Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia ». The New England Journal of Medicine 376, n^o 10 (09 2017): 917‑27. https://doi.org/10.1056/NEJMoa1609324.

Hoffmann, V. S., M. Baccarani, J. Hasford, F. Castagnetti, F. Di Raimondo, L. F. Casado, A. Turkina, et al. « Treatment and Outcome of 2904 CML Patients from the EUTOS Population-Based Registry ». Leukemia 31, n^o 3 (2017): 593‑601. https://doi.org/10.1038/leu.2016.246.

Ilander, M., U. Olsson-Strömberg, H. Schlums, J. Guilhot, O. Brück, H. Lähteenmäki, T. Kasanen, et al. « Increased Proportion of Mature NK Cells Is Associated with Successful Imatinib Discontinuation in Chronic Myeloid Leukemia ». Leukemia 31, n^o 5 (2017): 1108‑16. https://doi.org/10.1038/leu.2016.360.

Jacomet, Florence, Emilie Cayssials, Alice Barbarin, Deborah Desmier, Sara Basbous, Lucie Lefèvre, Anaïs Levescot, et al. « The Hypothesis of the Human INKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia ». Frontiers in Immunology 7 (2016): 688. https://doi.org/10.3389/fimmu.2016.00688.

Leblond, Véronique, Pierre Morel, Marie-Sarah Dilhuidy, Xavier Leleu, Carole Soussain, Stéphane Leprête, Brigitte Dreyfus, et al. « A Phase II Bayesian Sequential Clinical Trial in Advanced Waldenström Macroglobulinemia Patients Treated with Bortezomib: Interest of Addition of Dexamethasone ». Leukemia & Lymphoma 58, n^o 11 (2017): 2615‑23. https://doi.org/10.1080/10428194.2017.1307357.

Lemelle, Lauriane, Gaëlle Pierron, Paul Fréneaux, Sophie Huybrechts, Alexandra Spiegel, Dominique Plantaz, Morbize Julieron, et al. « NUT Carcinoma in Children and Adults: A Multicenter Retrospective Study ». Pediatric Blood & Cancer 64, n^o 12 (décembre 2017). https://doi.org/10.1002/pbc.26693.

Manier, Salomon, Xavier Leleu, et Hervé Avet-Loiseau. « [Circulating exosomal microRNA as biomarkers in mutiple myeloma] ». Medecine Sciences: M/S 33, n^o 11 (novembre 2017): 939‑41. https://doi.org/10.1051/medsci/20173311008.

Millot, Frédéric, Christelle Dupraz, Joelle Guilhot, Meinolf Suttorp, Françoise Brizard, Thierry Leblanc, Adalet Meral Güneş, et al. « Additional Cytogenetic Abnormalities and Variant t(9;22) at the Diagnosis of Childhood Chronic Myeloid Leukemia: The Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents ». Cancer 123, n^o 18 (15 septembre 2017): 3609‑16. https://doi.org/10.1002/cncr.30767.

Millot, Frédéric, Joëlle Guilhot, Meinolf Suttorp, Adalet Meral Güneş, Petr Sedlacek, Eveline De Bont, Chi Kong Li, et al. « Prognostic Discrimination Based on the EUTOS Long-Term Survival Score within the International Registry for Chronic Myeloid Leukemia in Children and Adolescents ». Haematologica 102, n^o 10 (2017): 1704‑8. https://doi.org/10.3324/haematol.2017.170035.

Mondelaers, Veerle, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Françoise Mazingue, Geneviève Plat, Karima Yakouben, et al. « Prolonged versus Standard Native E. Coli Asparaginase Therapy in Childhood Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: Final Results of the EORTC-CLG Randomized Phase III Trial 58951 ». Haematologica 102, n^o 10 (2017): 1727‑38. https://doi.org/10.3324/haematol.2017.165845.

Piette, C., S. Suciu, E. Clappier, Y. Bertrand, S. Drunat, S. Girard, K. Yakouben, et al. « Differential Impact of Drugs on the Outcome of ETV6-RUNX1 Positive Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia: Results of the EORTC CLG 58881 and 58951 Trials ». Leukemia 32, n^o 1 (2018): 244‑48. https://doi.org/10.1038/leu.2017.289.

Poulain, Stéphanie, Christophe Roumier, Elisabeth Bertrand, Aline Renneville, Aurélie Caillault-Venet, Emmanuelle Doye, Sandrine Geffroy, et al. « TP53 Mutation and Its Prognostic Significance in Waldenstrom’s Macroglobulinemia ». Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23, n^o 20 (15 octobre 2017): 6325‑35. https://doi.org/10.1158/1078-0432.CCR-17-0007.

Rea, Delphine, Guylaine Henry, Zena Khaznadar, Gabriel Etienne, François Guilhot, Franck Nicolini, Joelle Guilhot, et al. « Natural Killer-Cell Counts Are Associated with Molecular Relapse-Free Survival after Imatinib Discontinuation in Chronic Myeloid Leukemia: The IMMUNOSTIM Study ». Haematologica 102, n^o 8 (2017): 1368‑77. https://doi.org/10.3324/haematol.2017.165001.

Rea, Delphine, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joelle Guilhot, Agnès Guerci-Bresler, Martine Gardembas, et al. « Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G-TKI Study ». Blood 129, n^o 7 (16 2017): 846‑54. https://doi.org/10.1182/blood-2016-09-742205.

Rousselot, Philippe, Stéphane Prost, Joelle Guilhot, Lydia Roy, Gabriel Etienne, Laurence Legros, Aude Charbonnier, et al. « Pioglitazone Together with Imatinib in Chronic Myeloid Leukemia: A Proof of Concept Study ». Cancer 123, n^o 10 (15 2017): 1791‑99. https://doi.org/10.1002/cncr.30490.

Schorb, E., C. P. Fox, K. Fritsch, L. Isbell, A. Neubauer, A. Tzalavras, R. Witherall, et al. « High-Dose Thiotepa-Based Chemotherapy with Autologous Stem Cell Support in Elderly Patients with Primary Central Nervous System Lymphoma: A European Retrospective Study ». Bone Marrow Transplantation 52, n^o 8 (août 2017): 1113‑19. https://doi.org/10.1038/bmt.2017.23.

Schütz, C., S. Inselmann, S. Saussele, C. T. Dietz, M. C. Mu Ller, E. Eigendorff, C. A. Brendel, et al. « Expression of the CTLA-4 Ligand CD86 on Plasmacytoid Dendritic Cells (PDC) Predicts Risk of Disease Recurrence after Treatment Discontinuation in CML ». Leukemia 31, n^o 4 (2017): 829‑36. https://doi.org/10.1038/leu.2017.9.

Sens, Florence, Déborah Chaintreuil, Anne Jolivot, Fitsum Guebre-Egziabher, Philip Robinson, Lionel Karlin, Frank Bridoux, et Laurent Juillard. « Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study ». American Journal of Nephrology 46, n^o 5 (2017): 355‑63. https://doi.org/10.1159/000481461.

Vignon, Marguerite, Camille Cohen, Stanislas Faguer, Laure-Hélène Noel, Celine Guilbeau, Marion Rabant, Sarah Higgins, et al. « The Clinicopathologic Characteristics of Kidney Diseases Related to Monotypic IgA Deposits ». Kidney International 91, n^o 3 (2017): 720‑28. https://doi.org/10.1016/j.kint.2016.10.026.

 

2016

Basbous, Sara, Anaïs Levescot, Nathalie Piccirilli, Françoise Brizard, François Guilhot, Lydia Roy, Nicolas Bourmeyster, Jean-Marc Gombert, et André Herbelin. « The Rho-ROCK Pathway as a New Pathological Mechanism of Innate Immune Subversion in Chronic Myeloid Leukaemia ». The Journal of Pathology 240, n^o 3 (2016): 262‑68. https://doi.org/10.1002/path.4779.

Boyle, Eileen, Salomon Manier, Julie Lejeune, Guillemette Fouquet, Stephanie Guidez, Sarah Bonnet, Houria Debarri, et al. « IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström’s Macroglobulinaemia ». Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22, n^o 20 (15 octobre 2016): 5152‑58. https://doi.org/10.1158/1078-0432.CCR-15-2899.

Bridoux, Frank, Nianhang Chen, Stephane Moreau, Bertrand Arnulf, Eric Moumas, Julie Abraham, Estelle Desport, Arnaud Jaccard, et Jean Paul Fermand. « Pharmacokinetics, Safety, and Efficacy of Lenalidomide plus Dexamethasone in Patients with Multiple Myeloma and Renal Impairment ». Cancer Chemotherapy and Pharmacology 78, n^o 1 (juillet 2016): 173‑82. https://doi.org/10.1007/s00280-016-3068-9.

Cayssials, Emilie, et Francois Guilhot. « Beyond Tyrosine Kinase Inhibitors: Combinations and Other Agents ». Best Practice & Research. Clinical Haematology 29, n^o 3 (2016): 271‑83. https://doi.org/10.1016/j.beha.2016.10.017.

De Veirman, Kim, Jinheng Wang, Song Xu, Xavier Leleu, Eddy Himpe, Ken Maes, Elke De Bruyne, et al. « Induction of MiR-146a by Multiple Myeloma Cells in Mesenchymal Stromal Cells Stimulates Their pro-Tumoral Activity ». Cancer Letters 377, n^o 1 (10 2016): 17‑24. https://doi.org/10.1016/j.canlet.2016.04.024.

Deininger, Michael W., J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, et al. « Compound Mutations in BCR-ABL1 Are Not Major Drivers of Primary or Secondary Resistance to Ponatinib in CP-CML Patients ». Blood 127, n^o 6 (11 février 2016): 703‑12. https://doi.org/10.1182/blood-2015-08-660977.

Dejoie, Thomas, Jill Corre, Helene Caillon, Cyrille Hulin, Aurore Perrot, Denis Caillot, Eileen Boyle, et al. « Serum Free Light Chains, Not Urine Specimens, Should Be Used to Evaluate Response in Light-Chain Multiple Myeloma ». Blood 128, n^o 25 (22 2016): 2941‑48. https://doi.org/10.1182/blood-2016-07-726778.

Geyer, Holly L., Heidi Kosiorek, Amylou C. Dueck, Robyn Scherber, Stefanie Slot, Sonja Zweegman, Peter Aw Te Boekhorst, et al. « Associations between Gender, Disease Features and Symptom Burden in Patients with Myeloproliferative Neoplasms: An Analysis by the MPN QOL International Working Group ». Haematologica 102, n^o 1 (2017): 85‑93. https://doi.org/10.3324/haematol.2016.149559.

Guilhot, François. « Cytogenetics in CML: More Important than You Think ». Blood 127, n^o 22 (02 2016): 2661‑62. https://doi.org/10.1182/blood-2016-04-708206.

Herbaux, Charles, Elisabeth Bertrand, Guillemette Marot, Christophe Roumier, Nicolas Poret, Valérie Soenen, Olivier Nibourel, et al. « BACH2 Promotes Indolent Clinical Presentation in Waldenström Macroglobulinemia ». Oncotarget 8, n^o 34 (22 août 2017): 57451‑59. https://doi.org/10.18632/oncotarget.9917.

Hulin, Cyrille, Andrew Belch, Chaim Shustik, Maria Teresa Petrucci, Ulrich Dührsen, Jin Lu, Kevin Song, et al. « Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial ». Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34, n^o 30 (20 2016): 3609‑17. https://doi.org/10.1200/JCO.2016.66.7295.

Khoury, Hanna J., Stuart L. Goldberg, Michael J. Mauro, Richard M. Stone, Michael W. Deininger, M. Brigid Bradley-Garelik, Hesham Mohamed, et François Guilhot. « Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia ». Clinical Lymphoma, Myeloma & Leukemia 16, n^o 6 (2016): 341-349.e1. https://doi.org/10.1016/j.clml.2016.03.004.

Lipton, Jeffrey H., Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, et al. « Ponatinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukaemia: An International, Randomised, Open-Label, Phase 3 Trial ». The Lancet. Oncology 17, n^o 5 (2016): 612‑21. https://doi.org/10.1016/S1470-2045(16)00080-2.

Padula, William V., Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, et al. « Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States ». Journal of the National Cancer Institute 108, n^o 7 (juillet 2016). https://doi.org/10.1093/jnci/djw003.

Pfirrmann, M., M. Baccarani, S. Saussele, J. Guilhot, F. Cervantes, G. Ossenkoppele, V. S. Hoffmann, et al. « Prognosis of Long-Term Survival Considering Disease-Specific Death in Patients with Chronic Myeloid Leukemia ». Leukemia 30, n^o 1 (janvier 2016): 48‑56. https://doi.org/10.1038/leu.2015.261.

 

2015

PubMed. « 25196702 25346428 25435115 25573033 25783795 25903796 26050650 26118501 26474455 26484337 26511135 26603508 26688235 – Search Results ». Consulté le 25 juin 2020. https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/?term=25196702+25346428+25435115+25573033+25783795+25903796+26050650+26118501+26474455+26484337+26511135+26603508+26688235.

Aladjidi, Nathalie, Helder Fernandes, Thierry Leblanc, Amélie Vareliette, Frédéric Rieux-Laucat, Yves Bertrand, Hervé Chambost, et al. « Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort ». Frontiers in Pediatrics 3 (2015): 79. https://doi.org/10.3389/fped.2015.00079.

Brümmendorf, Tim H., Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis, et Carlo Gambacorti-Passerini. « Bosutinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia: Results from the 24-Month Follow-up of the BELA Trial ». British Journal of Haematology 168, n^o 1 (janvier 2015): 69‑81. https://doi.org/10.1111/bjh.13108.

Bruzzoni-Giovanelli, Heriberto, Juan R. González, François Sigaux, Bruno O. Villoutreix, Jean Michel Cayuela, Joëlle Guilhot, Claude Preudhomme, François Guilhot, Jean-Luc Poyet, et Philippe Rousselot. « Genetic Polymorphisms Associated with Increased Risk of Developing Chronic Myelogenous Leukemia ». Oncotarget 6, n^o 34 (3 novembre 2015): 36269‑77. https://doi.org/10.18632/oncotarget.5915.

Clappier, E., N. Grardel, M. Bakkus, J. Rapion, B. De Moerloose, P. Kastner, A. Caye, et al. « IKZF1 Deletion Is an Independent Prognostic Marker in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia, and Distinguishes Patients Benefiting from Pulses during Maintenance Therapy: Results of the EORTC Children’s Leukemia Group Study 58951 ». Leukemia 29, n^o 11 (novembre 2015): 2154‑61. https://doi.org/10.1038/leu.2015.134.

Dkhissi, Fatima, Djamel Aggoune, Julien Pontis, Nathalie Sorel, Nathalie Piccirilli, Amélie LeCorf, François Guilhot, Jean-Claude Chomel, Slimane Ait-Si-Ali, et Ali G. Turhan. « The Downregulation of BAP1 Expression by BCR-ABL Reduces the Stability of BRCA1 in Chronic Myeloid Leukemia ». Experimental Hematology 43, n^o 9 (septembre 2015): 775‑80. https://doi.org/10.1016/j.exphem.2015.04.013.

Guilhot, Joëlle, Claude Preudhomme, Francois Xavier Mahon, et François Guilhot. « Analyzing Molecular Response in Chronic Myeloid Leukemia Clinical Trials: Pitfalls and Golden Rules ». Cancer 121, n^o 4 (15 février 2015): 490‑97. https://doi.org/10.1002/cncr.29053.

Hijiya, Nobuko, Frederic Millot, et Meinolf Suttorp. « Chronic Myeloid Leukemia in Children: Clinical Findings, Management, and Unanswered Questions ». Pediatric Clinics of North America 62, n^o 1 (février 2015): 107‑19. https://doi.org/10.1016/j.pcl.2014.09.008.

Hijiya, Nobuko, Kirk R. Schultz, Markus Metzler, Frederic Millot, et Meinolf Suttorp. « Pediatric Chronic Myeloid Leukemia Is a Unique Disease That Requires a Different Approach ». Blood 127, n^o 4 (28 janvier 2016): 392‑99. https://doi.org/10.1182/blood-2015-06-648667.

Hoffmann, V. S., M. Baccarani, J. Hasford, D. Lindoerfer, S. Burgstaller, D. Sertic, P. Costeas, et al. « The EUTOS Population-Based Registry: Incidence and Clinical Characteristics of 2904 CML Patients in 20 European Countries ». Leukemia 29, n^o 6 (juin 2015): 1336‑43. https://doi.org/10.1038/leu.2015.73.

Jacomet, Florence, Emilie Cayssials, Sara Basbous, Anaïs Levescot, Nathalie Piccirilli, Deborah Desmier, Aurélie Robin, et al. « Evidence for Eomesodermin-Expressing Innate-like CD8(+) KIR/NKG2A(+) T Cells in Human Adults and Cord Blood Samples ». European Journal of Immunology 45, n^o 7 (juillet 2015): 1926‑33. https://doi.org/10.1002/eji.201545539.

Millot, Frédéric, et Meinolf Suttorp. « Managing Children with Chronic Myeloid Leukaemia–Response to Baccarani ». British Journal of Haematology 169, n^o 5 (juin 2015): 760‑61. https://doi.org/10.1111/bjh.13249.

Omuro, Antonio, Olivier Chinot, Luc Taillandier, Hervé Ghesquieres, Carole Soussain, Vincent Delwail, Thierry Lamy, et al. « Methotrexate and Temozolomide versus Methotrexate, Procarbazine, Vincristine, and Cytarabine for Primary CNS Lymphoma in an Elderly Population: An Intergroup ANOCEF-GOELAMS Randomised Phase 2 Trial ». The Lancet. Haematology 2, n^o 6 (juin 2015): e251-259. https://doi.org/10.1016/S2352-3026(15)00074-5.

Puyade, M., G. Defossez, F. Guilhot, et P. Ingrand. « Multiple Myeloma: The Quality of Care Is Linked to Geographical and Organisational Determinants. A Study in a French Registry ». European Journal of Cancer Care 25, n^o 5 (septembre 2016): 855‑63. https://doi.org/10.1111/ecc.12414.

• American Society of Hematology
• European Society of Hematology
• Société Française d’Hématologie
• European Leukemia net
• France Intergroupe de la Leucémie Myéloïde Chronique